<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl4">
 <label>Table 4</label>
 <caption>
  <p>Vaccines against SARS-CoV-2 undergoing clinical trials as of May 27, 2020 (
   <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov" id="intref0075" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov</ext-link>; 
   <ext-link ext-link-type="uri" xlink:href="https://chictr.org.cn" id="intref0065" xmlns:xlink="http://www.w3.org/1999/xlink">https://chictr.org.cn</ext-link>).
  </p>
 </caption>
 <alt-text id="alttext0070">Table 4</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Name</th>
    <th>Type of Vaccine</th>
    <th>Developer</th>
    <th>Comments</th>
    <th>Clinical Trials</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Ad5nCoV</td>
    <td align="left">Recombinant adenovirus type 5 vector (Non-replicating)</td>
    <td align="left">CanSino Biological Inc. and Beijing Institute of Biotechnology.</td>
    <td align="left">Engineered genetically to express SARS-CoV-2 spike (S) protein with replication-defective adenovirus type 5 as a vector.</td>
    <td align="left">Phase I NCT04313127,
     <break/>Phase II NCT04341389,
     <break/>Phase I
     <break/>ChiCTR2000030906.
    </td>
   </tr>
   <tr>
    <td align="left">mRNA 1273</td>
    <td align="left">novel lipid nanoparticle (LNP)- encapsulated mRNA</td>
    <td align="left">Moderna/ National Institute of Allergy and Infectious Diseases (NIAID).</td>
    <td align="left">The mRNA-1273 vaccine contains an mRNA that encodes for prefusion stabilized SARS-CoV-2 spike protein.</td>
    <td align="left">Phase I NCT04283461,
     <break/>Phase II NCT04405076.
    </td>
   </tr>
   <tr>
    <td align="left">INO- 4800</td>
    <td align="left">DNA plasmid</td>
    <td align="left">Inovio Pharmaceuticals.</td>
    <td align="left">Plasmid encoding S protein is transported into cells by electroporation using a device known as CELLECTRA.</td>
    <td align="left">Phase I
     <break/>NCT04336410.
    </td>
   </tr>
   <tr>
    <td align="left">aAPCs</td>
    <td align="left">Lentiviral vector-based artificial antigen-presenting cells (aAPC)</td>
    <td align="left">Shenzhen Geno-Immune Medical Institute.</td>
    <td align="left">aAPCs vaccine is a lentiviral-based vector system made to express viral proteins and immune-modulatory genes to modify aAPC and to activate T cells.</td>
    <td align="left">Phase I
     <break/>NCT04299724.
    </td>
   </tr>
   <tr>
    <td align="left">Lentiviral Minigene Vaccine (LV-SMENP) DC</td>
    <td align="left">Lentiviral vector-based dendritic cells</td>
    <td align="left">Shenzhen Geno-Immune Medical Institute.</td>
    <td align="left">It is made by modification of dendritic cells with a lentivirus vector made to express SARS-CoV-2 minigene SMENP and immune-modulatory genes.</td>
    <td align="left">Phase I
     <break/>NCT04276896.
    </td>
   </tr>
   <tr>
    <td align="left">Bacille Calmette-Guérin (BCG)</td>
    <td align="left">Live attenuated strain of 
     <italic>Mycobacterium bovis</italic>
    </td>
    <td align="left">Albert Calmette and Camille Guérin.</td>
    <td align="left">BCG vaccine is used against tuberculosis. In various 
     <italic>in vitro</italic> and 
     <italic>in vivo</italic> studies, it has been shown to protect against other respiratory tract infections and reported noteworthy decreases in morbidity and mortality. The hypothesis behind the trial is that BCG vaccination induces partial protection against the susceptibility to SARS-CoV-2 infection.
    </td>
    <td align="left">Phase III
     <break/>NCT04327206,
     <break/>Phase III
     <break/>NCT04328441,
     <break/>Phase III
     <break/>NCT04379336,
     <break/>Phase IV
     <break/>NCT04348370.
    </td>
   </tr>
   <tr>
    <td align="left">AZD1222(ChAdOx1 nCoV-19)</td>
    <td align="left">Adenovirus vector-based vaccines</td>
    <td align="left">University of Oxford/Astra Zeneca.</td>
    <td align="left">Adenovirus (attenuated) expressing the SARS-CoV-2 spike protein.</td>
    <td align="left">Phase I\II
     <break/>NCT04324606.
    </td>
   </tr>
   <tr>
    <td align="left">NVX-CoV2373</td>
    <td align="left">SARS-COV-2 rS nanoparticle vaccine with or without matrix-M adjuvant</td>
    <td align="left">Novavax.</td>
    <td align="left">NVX-CoV2373 is a stable prefusion protein prepared using nanoparticle technology, whereas matrix-M adjuvant is used to increase the immune response.</td>
    <td align="left">Phase I/II
     <break/>NCT04368988.
    </td>
   </tr>
   <tr>
    <td align="left">BNT162a1
     <break/>BNT162b1
     <break/>BNT162b2
     <break/>BNT162c2
    </td>
    <td align="left">RNA vaccines</td>
    <td align="left">BioNTech and Pfizer Inc.</td>
    <td align="left">Two of the vaccine candidates include a modified nucleoside mRNA (modRNA); one candidate uses self-amplifying mRNA (saRNA), whereas the other one contains uridine containing mRNA (uRNA). Each mRNA setup is joined with a lipid nanoparticle (LNP) formulation, and the receptor-binding domain (RBD) of the vaccines contain the piece of the spike, which is essential for eliciting antibodies that can inactivate the virus.</td>
    <td align="left">Phase I/II
     <break/>NCT04368728,
     <break/>Phase I/II
     <break/>NCT04380701.
    </td>
   </tr>
   <tr>
    <td align="left">V-SARS</td>
    <td align="left">Plasma</td>
    <td align="left">Immunitor LLC.</td>
    <td align="left">A heat-inactivated vaccine prepared from the plasma of donors infected with COVID-19.</td>
    <td align="left">Phase I/II
     <break/>NCT04380532.
    </td>
   </tr>
   <tr>
    <td align="left">CoronaVac</td>
    <td align="left">Inactivated vaccine</td>
    <td align="left">Sinovac Biotech Co. Ltd.</td>
    <td align="left">Inactive type of viral vaccines is made by proliferating viruses in cell culture, followed by inactivation through chemical means. Vaccination of inactivated vaccines permits the body to produce an immune response against introduced viral antigens without having an actual threat of being infected since the virus is inactive.</td>
    <td align="left">Phase I/II
     <break/>NCT04352608.
    </td>
   </tr>
   <tr>
    <td align="left">Inactivated vaccine</td>
    <td align="left">Inactivated</td>
    <td align="left">Beijing Institute of Biological Products Co., LTD.</td>
    <td align="left">Inactive type of viral vaccines is synthesized by proliferating viruses in cell culture, followed by inactivation through chemical means. Vaccination of inactivated vaccines permits the body to produce an immune response against introduced viral antigens without having an actual threat of being infected since the virus is inactive.</td>
    <td align="left">Phase I/II
     <break/>ChiCTR2000032459.
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
